XTRA:BAYNPharmaceuticals
Supreme Court Roundup Case Puts Bayer Litigation And Cash Flows In Focus
The U.S. Supreme Court heard arguments on Bayer's Roundup federal preemption case involving glyphosate warning labels.
The hearing centers on whether EPA approval of Roundup labeling blocks state failure to warn claims alleging cancer risk.
The outcome could influence over 100,000 related cases and the scale of XTRA:BAYN's litigation exposure in the U.S.
Bayer, listed as XTRA:BAYN, is a diversified life sciences group with core operations in pharmaceuticals, consumer health, and crop...